Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura.
Discrepant outcomes of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura have been reported. Here patients with dyspepsia and no other complications underwent gastroendoscopic examination and evaluation for Helicobacter pylori infection. Helicobacter pylori-infected patients with gastritis and gastric ulcer received eradication therapy: lansoprazole (60 mg/day), clarithromycin (400 mg/day), and amoxicillin (1500 mg/day) for 1 week. Lansoprazole 30 mg/day was administrated additional 7 weeks. Peripheral platelets were counted before treatment, 8 weeks after initiation of therapy, and at follow-up periods. Platelet counts in patients with both gastritis and gastric ulcer were evaluated with reference to the presence of Helicobacter pylori infection. Eighty-seven patients with gastritis and 35 of those with gastric ulcer underwent successful eradication therapy. Peripheral platelet counts in patients with gastritis decreased from 235+/-55 to 228+/-58 (10(3)/microL) (p=0.0337), and those with gastric ulcer decreased from 248+/-60 to 232+/-48 (10(3)/microL) (p=0.020) 8 weeks after initiation of therapy. Non-eradicated patients did not show such a tendency. Helicobacter pylori eradication reduced peripheral platelet counts in patients with gastritis and gastric ulcer. Amelioration of thrombocytopenia by eradicating Helicobacter pylori appears to involve mechanisms specific to idiopathic thrombocytopenic purpura.
Matsukawa
Yoshihiro
Y
Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. m-2000@mbk.ocn.ne.jp
Kato
Kimitoshi
K
Hatta
Yoshihiro
Y
Iwamoto
Maho
M
Mizuno
Shigeaki
S
Kurihara
Ryuichi
R
Arakawa
Yasuyuki
Y
Kurosaka
Hanzo
H
Hayashi
Izumi
I
Sawada
Shigemasa
S
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000097:blood / Q000209:etiology / Q000382:microbiology; D005756:Gastritis / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic; D013276:Stomach Ulcer / Q000097:blood* / Q000209:etiology / Q000382:microbiology
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin